Showing 1 to 5 of 5 results
Australia Approves New Alzheimer's Drug, but High Cost and Limited Access Remain
Australia approved donanemab for early-stage Alzheimer's, offering a 33% slower decline rate but costing $80,000 and impacting only 10-20% of dementia patients due to genetic profile and other requirements; the drug's access is further limited by Medicare and Pharmaceutical Benefits Scheme exclusion...
Australia Approves New Alzheimer's Drug, but High Cost and Limited Access Remain
Australia approved donanemab for early-stage Alzheimer's, offering a 33% slower decline rate but costing $80,000 and impacting only 10-20% of dementia patients due to genetic profile and other requirements; the drug's access is further limited by Medicare and Pharmaceutical Benefits Scheme exclusion...
Progress
48% Bias Score
Antibiotic Drug Shows Promise for Chronic Back Pain
A new antibiotic drug, PP353, shows promise in treating chronic lower back pain caused by infection, with early trials indicating that 60% of 44 participants experienced significant pain and disability reduction; however, further trials are needed before widespread availability.
Antibiotic Drug Shows Promise for Chronic Back Pain
A new antibiotic drug, PP353, shows promise in treating chronic lower back pain caused by infection, with early trials indicating that 60% of 44 participants experienced significant pain and disability reduction; however, further trials are needed before widespread availability.
Progress
56% Bias Score
Breakthrough Asthma Drug Shows Promise in Clinical Trial
Researchers at King's College London announced a significant breakthrough in asthma treatment with the new drug Benralizumab, showing it drastically reduces the need for steroids in a clinical trial of 158 participants and offering hope for millions.
Breakthrough Asthma Drug Shows Promise in Clinical Trial
Researchers at King's College London announced a significant breakthrough in asthma treatment with the new drug Benralizumab, showing it drastically reduces the need for steroids in a clinical trial of 158 participants and offering hope for millions.
Progress
40% Bias Score
New Antibiotic Shows Promise Against Drug-Resistant Gonorrhea
A phase 3 clinical trial shows gepotidacin, a new antibiotic, effectively treats gonorrhea in 92.6% of participants, offering a crucial alternative as the infection develops resistance to existing treatments, with infection rates reaching a 30-year high in Canada.
New Antibiotic Shows Promise Against Drug-Resistant Gonorrhea
A phase 3 clinical trial shows gepotidacin, a new antibiotic, effectively treats gonorrhea in 92.6% of participants, offering a crucial alternative as the infection develops resistance to existing treatments, with infection rates reaching a 30-year high in Canada.
Progress
28% Bias Score
FDA Approves First New Pain Reliever in Over Two Decades
The FDA approved Journavx (suztrigine), a new non-opioid pain reliever, offering a safer alternative to opioids; clinical trials showed effectiveness in reducing post-surgical pain, but further research is needed for chronic pain.
FDA Approves First New Pain Reliever in Over Two Decades
The FDA approved Journavx (suztrigine), a new non-opioid pain reliever, offering a safer alternative to opioids; clinical trials showed effectiveness in reducing post-surgical pain, but further research is needed for chronic pain.
Progress
48% Bias Score
Showing 1 to 5 of 5 results